✦ LIBER ✦

The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia

✍ Scribed by Tarnani, M; D'Arena, G; Efremov, D G; Marietti, S; S, Sica; Leone, G; Laurenti, L

Book ID: 109887052
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 116 KB
Volume: 24
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2009.297

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab in B-Cell Chronic Lymphocyti

Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia

✍ Shapira, Ilan; Grossbard, Michael L. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 57 KB

Efficacy and safety of low-dose alemtuzu

Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia

✍ Laurenti, L; Tarnani, M; Efremov, D G; Chiusolo, P; De Padua, L; Sica, S; Leone, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 82 KB

Management Guidelines for Use of Alemtuz

Management Guidelines for Use of Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia

✍ Keating, Michael; Coutré, Stephen; Rai, Kanti; Österborg, Anders; Faderl, Stefan 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 172 KB

Low-dose alemtuzumab-associated immune t

Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia

✍ Gianluigi Reda; Francesco Maura; Giuseppe Gritti; Anna Gregorini; Francesca Bind 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

High-dose glucocorticoids plus Ofatumuma

High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

✍ Vannata, Barbara; Innocenti, Idanna; Autore, Francesco; Sorà, Federica; Chiusolo 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

Routine clinical use of alemtuzumab in p

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia : A nation-wide retrospective study in Austria

✍ Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono